PMR

PMR2.jpg

NEJM: Polymyalgia Rheumatica

Jack Cush, MD

Drs. Dejaco and Matteson have published and update and review of polymyalgia rheumatica (PMR) in the NEJM. They lay out the initial approach to diagnosis, initial steroid dosing, management over time and when to use steroid sparing therapy.

Read Article
RheumNow Podcast square

Rheumatology Pitfalls (3.20.2026)

Jack Cush, MD

Dr. Jack Cush reviews the regulatory actions, news and journal reports from this past week on RheumNow.com.

Read Article
Cross-sectional study of 180 PMR pts compared dz activity by PMR-AS to Systemic Immune-Inflammation Index (SII = Plts × PMNs/Lymphs) using CBC.48% had mod-hi dz (PMR-AS >=7). SII had moderate correlation with PMR-AS (r = 0.47), possibly useful in monitoring PMR https://t.co/vG1alSdVRU
Dr. John Cush @RheumNow( View Tweet )
Screen%20Shot%202018-11-01%20at%2010.14.03%20AM_0.png

Rheumatic Immune-related Adverse Effects with Checkpoint Inhibitor Therapy

Jack Cush, MD

A retrospective study of patients who developed rheumatic immune-related adverse events (R-irAEs) after receiving immune checkpoint inhibitors (ICIs) at two oncology centers in Spain suggests that early recognition can lead to effective management that allows continuation of cancer therapy.

Read Article
RheumNow Podcast square

UBER Rheumatology Ride (3.6.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this week on RheumNow.com

Read Article
What did you miss at RheumNow Live 2026? Our Poster Hall features new data across: • Psoriatic Arthritis • Systemic Lupus Erythematosus • Lupus Nephritis • Vasculitis • Polymyalgia Rheumatica • Axial Spondyloarthritis From Phase III trials to real-world evidence, these https://t.co/nuXGUdmwon
Dr. John Cush @RheumNow( View Tweet )
artangiogca.jpg

Giant Cell Arteritis Outcomes in Canada

Jack Cush, MD

A retrospective cohort study of patients with giant cell arteritis (GCA) demonstrates relapses are common and seen in nearly half of patients, were common after treatment is stopped and is not effectively averted by methotrexate (MTX).

Read Article
RheumNow Podcast square

2026 Resolutions (1.9.2026)

Jack Cush, MD

Dr. Jack Cush reviews the news, announcements and journal articles from this past week on RheumNow.com. More on Variable bendability, a better way to treat RA, and a novel advance for GLP1a in PsA; and 2026 Resolutions!

Read Article
58 newly Dx #PMR pts (on <8 wks steroids/GC) randomised 1:1 MTX 25 mg/wk or placebo, w/ 24-week GC-tapering protocol. @wk 52 GC-free remission achieved in 80% of MTX vs 46% of placebo pts (risk difference 34%, 1-sided 95% CI: 14%, 1-sided P = .0042) https://t.co/75SLx5LtqZ https://t.co/HtDAJe5VI2

Links:

Dr. John Cush @RheumNow( View Tweet )
GCA.glossary.wordle

Best of 2025: Glossary for Giant Cell Arteritis

Jack Cush, MD

Dejaco and colleagues have published a glossary of terms often used in conjunction with giant cell arteritis. The glossary of definitions for 23 signs and symptoms of GCA was developed through a consensus process involving international experts.

Read Article
Cases & Guidelines: Tuesday Night Rheumatology Panelists discuss their approaches to a range of difficult cases in multiple areas, including RA, PsA and PMR. Panelists: Audrey Gibson, PA-C; Benjamin A. Smith, PA-C; Emma Bavage, ANP; Jack Cush, MD https://t.co/vl5J9NYUKZ https://t.co/nsTf370bu9

Links:

Dr. John Cush @RheumNow( View Tweet )
Cases & Guidelines: Tuesday Night Rheumatology Panelists discuss their approaches to a range of difficult cases in multiple areas, including RA, PsA and PMR. Panelists: Audrey Gibson, PA-C; Benjamin A. Smith, PA-C; Emma Bavage, ANP; Jack Cush, MD https://t.co/1HPBdPdIVx https://t.co/30Q6azQU3r

Links:

Dr. John Cush @RheumNow( View Tweet )
APP QD Clinic: Unweanable PMR APP QD Clinic: Unweanable PMR Jack Cush, MD, and Leilani Law, APN, Dallas, TX, discuss a case regarding unweanable polymyalgia rheumatica. This APP QD clinic is presented as part of RheumNow's "Mission: APP Partners in Care" campaign during the https://t.co/Gl8iQJf1d2
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Turkey Tryptophan (11.28.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and reports from this past week on RheumNow.com, including reports on FDA resurrections, FM seasonal worsening, and do you fight switch or swap biologics in PsA TNFi nonresponders?

Read Article
In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ https://t.co/lIX4gDLjqd
Dr. John Cush @RheumNow( View Tweet )
In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ https://t.co/SsLVEyL8X8
Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

Treating During Pregnancy (11.14.2025)

Jack Cush, MD

Dr. Jack Cush reviews the journal articles, news and guidelines from this past week on RheumNow.com

Read Article
In 2024, 77 pts referred to Rheum for possible PMR were ultimately Dx w/ B19 viral infx. 96% had arthralgia & 7% had PMR-like features (5/5 w/ BL shoulder/neck. prolonged AM stiff, fever & Hi CRP/ESR - none had hip pain. 4/5 were male, w/ mean age of 55 yrs. None were RF/CCP+ https://t.co/AiK2K9whBH
Dr. John Cush @RheumNow( View Tweet )
#GCA & #PMR @ACRheum #ACR25 #gamechangers #ACRBest Yr 2 Select-GCA abst#776 #upadacitinib in yr2 of GCA REDUCES flares HELPFUL info ?ability to get drug for 2 yrs hopefully Failed Phase3 RCT of #secukinumab in #GCA helped #PMR abst#1175 & +Ph3 for PMR REPLENISH RCT @RheumNow https://t.co/5lH6HXhnfg

Links:

Janet Pope @Janetbirdope( View Tweet )
The next VEXAS, but also maybe we can treat it? IDH1/2 Another clonal hematopoesis known to cause heme malignancy, but also some inflamm sequelae (autoinflamm-like e.g. PMR/GCA) & you can directly inhibit it Wow. We will hear more #ACR25 LB21 @RheumNow https://t.co/WL2ai5zb8Q https://t.co/Yi31xkhLO9

Links:

David Liew @drdavidliew( View Tweet )
PMR patients need healthcare professionals who know a bit about their disease. Survey of US HCPs, amongst responders: - 68% were not aware/unsure about PMR - of those who were aware, knowledge was… not great (see below) PMR needs everyone’s respect #ACR25 ABST1617 @RheumNow https://t.co/SpyEnAW8lI

Links:

David Liew @drdavidliew( View Tweet )
REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/CLmCdBXiOf https://t.co/z20nWd2NSM

Links:

Dr. John Cush @RheumNow( View Tweet )
#1627 SLR informing the 2025 @eular_org recommendations for PMR & LVV 🔍 141 studies (30 RCTs) reviewed: new & further evidence for IL-6, JAK & B-cell-targeted therapies. Data will underpin updated management guidance. @RheumNow #ACR25

Mrinalini Dey @DrMiniDey( View Tweet )

#1614 Another SLR informing the 2025 EULAR recommendations for PMR & LVV 🧭 Fast-track clinics cut blindness & diagnostic delays; multimodal imaging pathways outperform biopsy alone. Key data shaping future referral & diagnosis guidance. @RheumNow #ACR25

Mrinalini Dey @DrMiniDey( View Tweet )

ACRmtg.jpg (keep)

ACR25 - Day 1 Report

Jack Cush, MD

ACR 2025 began today in Chicago with throngs of rheumatologists, fellows, ARP members, APPs and pharma folk taking to the meeting halls and rooms for tons of novel content. 

The annual meeting began with a great "Year in Review" featuring Drs.

Read Article

Therapeutic Updates

Diagnosis of PMR

RheumNow
Yates Thumbnail
Nine perspectives now available: Red Flags in the Diagnosis of PMR; Epidemiology of PMR; Role of the PCP in Diagnosis and Care; Importance of Diagnostic Imaging; ESR/CRP in PMR; PMR Must Rule Outs; Which PMR Patients Should Rheumatologists See?; Is There Hidden GCA?; and PMR Mimics.
Read Post

Recent Blogs

Best of 2023: PMR: glad or bad tidings?

Sarah Mackie, MRCP, PhD
Smile feedback opinion yes no good back opinion
Please don’t tell your patient that PMR “typically” lasts two years. According to real-world data from the UK, one in four patients with PMR is prescribed steroids by their primary care physician for over four years. But nobody tells them this at the start, and that causes big problems later on.
Read Post

Advancing PMR

Eric L. Matteson, MD, MPH
Dr. Eric Matteson
Even though polymyalgia rheumatica is not perceived by many physicians as a severe diagnosis, its diagnosis and management actually propose significant challenges. I'd like to talk about those challenges, and what directions our path forward can include to advance our understanding and improve the treatment of patients who have PMR.
Read Post

JAKi for PMR: Safe, or a Concern for Older Adults?

David Liew, FRACP
Dr. David Liew
JAK inhibitors obviously have dominated a lot of the discussion in our therapeutic landscape over the last couple of years. What about their use in polymyalgia rheumatica? Let's consider.
Read Post
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×